INT MEDICAL: September 2026 Filing Confirms Unchanged Share Capital and Adequate Public Float

Bulletin Express10-07

Shanghai INT Medical Instruments Co., Ltd. (INT MEDICAL) submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing on 7 October 2026, covering the month ended 30 September 2026.

Total authorised and issued capital • Authorised/registered share capital remained at RMB 211.20 million, representing 211.20 million H-class ordinary shares with a par value of RMB 1 each. • No changes were reported during the month; the balance at the beginning and end of September was identical.

Issued shares and treasury position • Issued shares: 211.20 million. • Treasury shares: none. • Consequently, the total number of issued shares stayed at 211.20 million with no cancellations, repurchases or new issues recorded.

Public float compliance • INT MEDICAL confirmed adherence to Main Board Rule 13.32D(1), maintaining at least the minimum 25 % public float required for its H-shares.

Capital instruments • The company reported no outstanding share options, warrants, convertible securities, or other equity-linked instruments. • No other share movements, Hong Kong Depositary Receipts or treasury-share transactions were disclosed.

Regulatory confirmations • The filing, signed by Chairman and Executive Director Liang Dongke, attested full compliance with all applicable listing rules and regulatory requirements for the period under review.

Overall, September 2026 saw a stable share-capital structure for INT MEDICAL with no equity dilution or corporate-action activity and continued compliance with Hong Kong listing regulations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1143289474?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-07 21:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143289474","market":"hk","top_or_hot":-1,"title":"INT MEDICAL: September 2026 Filing Confirms Unchanged Share Capital and Adequate Public Float","media":"Bulletin Express","content":"<p>Shanghai INT Medical Instruments Co., Ltd. (INT MEDICAL) submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing on 7 October 2026, covering the month ended 30 September 2026.</p>\n<p>Total authorised and issued capital  \n• Authorised/registered share capital remained at RMB 211.20 million, representing 211.20 million H-class ordinary shares with a par value of RMB 1 each.  \n• No changes were reported during the month; the balance at the beginning and end of September was identical.</p>\n<p>Issued shares and treasury position  \n• Issued shares: 211.20 million.  \n• Treasury shares: none.  \n• Consequently, the total number of issued shares stayed at 211.20 million with no cancellations, repurchases or new issues recorded.</p>\n<p>Public float compliance  \n• INT MEDICAL confirmed adherence to Main Board Rule 13.32D(1), maintaining at least the minimum 25 % public float required for its H-shares.</p>\n<p>Capital instruments  \n• The company reported no outstanding share options, warrants, convertible securities, or other equity-linked instruments.  \n• No other share movements, Hong Kong Depositary Receipts or treasury-share transactions were disclosed.</p>\n<p>Regulatory confirmations  \n• The filing, signed by Chairman and Executive Director Liang Dongke, attested full compliance with all applicable listing rules and regulatory requirements for the period under review.</p>\n<p>Overall, September 2026 saw a stable share-capital structure for INT MEDICAL with no equity dilution or corporate-action activity and continued compliance with Hong Kong listing regulations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INT MEDICAL: September 2026 Filing Confirms Unchanged Share Capital and Adequate Public Float</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINT MEDICAL: September 2026 Filing Confirms Unchanged Share Capital and Adequate Public Float\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-10-07 21:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai INT Medical Instruments Co., Ltd. (INT MEDICAL) submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing on 7 October 2026, covering the month ended 30 September 2026.</p>\n<p>Total authorised and issued capital  \n• Authorised/registered share capital remained at RMB 211.20 million, representing 211.20 million H-class ordinary shares with a par value of RMB 1 each.  \n• No changes were reported during the month; the balance at the beginning and end of September was identical.</p>\n<p>Issued shares and treasury position  \n• Issued shares: 211.20 million.  \n• Treasury shares: none.  \n• Consequently, the total number of issued shares stayed at 211.20 million with no cancellations, repurchases or new issues recorded.</p>\n<p>Public float compliance  \n• INT MEDICAL confirmed adherence to Main Board Rule 13.32D(1), maintaining at least the minimum 25 % public float required for its H-shares.</p>\n<p>Capital instruments  \n• The company reported no outstanding share options, warrants, convertible securities, or other equity-linked instruments.  \n• No other share movements, Hong Kong Depositary Receipts or treasury-share transactions were disclosed.</p>\n<p>Regulatory confirmations  \n• The filing, signed by Chairman and Executive Director Liang Dongke, attested full compliance with all applicable listing rules and regulatory requirements for the period under review.</p>\n<p>Overall, September 2026 saw a stable share-capital structure for INT MEDICAL with no equity dilution or corporate-action activity and continued compliance with Hong Kong listing regulations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01501","symbol_name":"瑛泰医疗","start_time":0,"source_url":"","article_id":"1143289474","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143289474","pubTimestamp":1791380664,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai INT Medical Instruments Co., Ltd. (INT MEDICAL) submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing on 7 October 2026, covering the month ended 30 September...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01501":"瑛泰医疗"},"translate_title":"INT MEDICAL：2026 年 9 月提交文件确认股本不变和足够的公众持股量","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01501":1},"content_text":"Shanghai INT Medical Instruments Co., Ltd. (INT MEDICAL) submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing on 7 October 2026, covering the month ended 30 September 2026.\nTotal authorised and issued capital  \n• Authorised/registered share capital remained at RMB 211.20 million, representing 211.20 million H-class ordinary shares with a par value of RMB 1 each.  \n• No changes were reported during the month; the balance at the beginning and end of September was identical.\nIssued shares and treasury position  \n• Issued shares: 211.20 million.  \n• Treasury shares: none.  \n• Consequently, the total number of issued shares stayed at 211.20 million with no cancellations, repurchases or new issues recorded.\nPublic float compliance  \n• INT MEDICAL confirmed adherence to Main Board Rule 13.32D(1), maintaining at least the minimum 25 % public float required for its H-shares.\nCapital instruments  \n• The company reported no outstanding share options, warrants, convertible securities, or other equity-linked instruments.  \n• No other share movements, Hong Kong Depositary Receipts or treasury-share transactions were disclosed.\nRegulatory confirmations  \n• The filing, signed by Chairman and Executive Director Liang Dongke, attested full compliance with all applicable listing rules and regulatory requirements for the period under review.\nOverall, September 2026 saw a stable share-capital structure for INT MEDICAL with no equity dilution or corporate-action activity and continued compliance with Hong Kong listing regulations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1143289474","isCrawlerRequest":true}